319 related articles for article (PubMed ID: 7536945)
21. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
[TBL] [Abstract][Full Text] [Related]
22. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Küfferle B; Brücke T; Topitz-Schratzberger A; Tauscher J; Gössler R; Vesely C; Asenbaum S; Podreka I; Kasper S
Psychiatry Res; 1996 Nov; 68(1):23-30. PubMed ID: 9027930
[TBL] [Abstract][Full Text] [Related]
23. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
[TBL] [Abstract][Full Text] [Related]
24. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
25. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
Travis MJ; Busatto GF; Pilowsky LS; Mulligan R; Acton PD; Gacinovic S; Mertens J; Terrière D; Costa DC; Ell PJ; Kerwin RW
Br J Psychiatry; 1998 Sep; 173():236-41. PubMed ID: 9926100
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
[TBL] [Abstract][Full Text] [Related]
27. New antipsychotics: classification, efficacy, and adverse effects.
Gerlach J
Schizophr Bull; 1991; 17(2):289-309. PubMed ID: 1715608
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
Farde L; Nyberg S; Oxenstierna G; Nakashima Y; Halldin C; Ericsson B
J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):19S-23S. PubMed ID: 7537284
[TBL] [Abstract][Full Text] [Related]
29. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
30. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.
Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Murray RM; Kerwin RW
Br J Psychiatry; 1994 Jan; 164(1):16-26. PubMed ID: 8137105
[TBL] [Abstract][Full Text] [Related]
31. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
[TBL] [Abstract][Full Text] [Related]
32. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
33. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Knable MB; Heinz A; Raedler T; Weinberger DR
Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
[TBL] [Abstract][Full Text] [Related]
34. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
35. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Stephenson C; Kerwin RW; Pilowsky LS
Br J Psychiatry; 1999 Sep; 175():231-8. PubMed ID: 10645324
[TBL] [Abstract][Full Text] [Related]
36. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
[TBL] [Abstract][Full Text] [Related]
37. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
Corripio I; Ferreira A; Portella MJ; Pérez V; Escartí MJ; Del Valle Camacho M; Sauras RB; Alonso A; Grasa EM; Carrió I; Catafau AM; Alvarez E
Psychiatry Res; 2012 Jan; 201(1):73-7. PubMed ID: 22281201
[TBL] [Abstract][Full Text] [Related]
38. Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study.
Hall H; Halldin C; Nyberg S; Farde L; Sedvall G
Eur Neuropsychopharmacol; 1995 Mar; 5(1):19-25. PubMed ID: 7542051
[TBL] [Abstract][Full Text] [Related]
39. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.
Kane JM
Drugs; 1993 Oct; 46(4):585-93. PubMed ID: 7506647
[TBL] [Abstract][Full Text] [Related]
40. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
